Drug Profile
Research programme: anti-CD3 monoclonal antibody - Verenium
Latest Information Update: 06 Dec 2010
Price :
$50
*
At a glance
- Originator Verenium Corporation
- Class Monoclonal antibodies
- Mechanism of Action CD3 antigen inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Autoimmune disorders; Transplant rejection
Most Recent Events
- 14 May 2008 The programme is available for licensing (http://www.verenium.com)
- 14 May 2008 Preclinical trials in Autoimmune disorders in USA (Parenteral)
- 14 May 2008 Preclinical trials in Transplant rejection in USA (Parenteral)